Evidence map›Paper›PMID 27493893›Full record

ArticleLiver cancer2016

Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis.

Satoshi Kitai, Masatoshi Kudo, Naoshi Nishida, Namiki Izumi, Michiie Sakamoto, Yutaka Matsuyama, Takafumi Ichida, Osamu Nakashima, Osamu Matsui, Yonson Ku and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan.Hepatology research : the official journal of the Japan Society of Hepatology · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Satoshi KitaiDepartment of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan.
Masatoshi KudoDepartment of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan.
Naoshi NishidaDepartment of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan.
Namiki IzumiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Michiie SakamotoDepartment of Pathology, Keio University School of Medicine, Tokyo, Japan.
Yutaka MatsuyamaDepartment of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan.
Takafumi IchidaShonan-East General Hospital, Kanagawa, Japan.
Osamu NakashimaDepartment of Clinical Laboratory Medicine, Kurume University Hospital, Kurume, Japan.
Osamu MatsuiDepartment of Radiology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Yonson KuhDepartment of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Norihiro KokudoHepato-Biliary-Pancreatic Surgery Division, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Masatoshi MakuuchiDepartment of Surgery, Japanese Red Cross Medical Center, Tokyo, Japan.
Liver Cancer Study Group of Japan
Kindai University · JPThe University of Tokyo · JPJapanese Red Cross Medical Center · JPKanazawa University · JPKeio University · JPKobe University · JPKurume University Hospital · JPMusashino Red Cross Hospital · JPShonan Kamakura General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsHepatocellular carcinoma (HCC) with decompensated liver cirrhosis (LC) is a life-threatening condition, which is amenable to liver transplantation (LT) as the standard first-line treatment. However, the application of LT can be limited due to a shortage of donor livers. This study aimed to clarify the effect of non-surgical therapy on the survival of patients with HCC and decompensated LC.

methodsOf the 58,886 patients with HCC registered in the nationwide survey of the Liver Cancer Study Group of Japan (January 2000-December 2005), we included 1,344 patients with primary HCC and Child-Pugh (C-P) grade C for analysis in this retrospective study. Among the patients analyzed, 108 underwent LT, 273 were treated by local ablation therapy (LAT), 370 were treated by transarterial chemoembolization (TACE), and 593 received best supportive care (BSC). The effect of LT, LAT, and TACE on overall survival (OS) was analyzed using multivariate and propensity score analyses.

resultsPatient characteristics did not differ significantly between each treatment group and the BSC group, after propensity score matching. LAT (hazard ratio [HR]) =0.568; 95% confidence interval [CI], 0.40-0.80) and TACE (HR=0.691; 95% CI, 0.50-0.96) were identified as significant contributors to OS if the C-P score was less than 11 and tumor conditions met the Milan criteria.

conclusionsFor patients with HCC within the Milan criteria and with a C-P score of 10 or 11, locoregional treatment can be used as a salvage treatment if LT is not feasible.

Indexed as

Best supportive careChild-Pugh grade CLocal ablation therapyTransarterial chemoembolization

Identifiers

PMID27493893
PMCPMC4960362
OpenAlexW2345644643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.